Robert Ford, Chairman and CEO, reported organic sales growth of 7.5% excluding COVID test sales, highlighting double-digit growth in Medical Devices and high single-digit growth in Established ...
The company expects consolidated fourth quarter net sales to decrease 10% to 15% sequentially, with adjusted EBITDA between $130 million and $160 million. Full year 2025 sales are anticipated between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results